Local Turkey

A new phase has started for Turkey’s Domestic Covid-19 vaccine: It is carried out in three groups

Variant tests for the virus-like particle (VLP) based domestic Covid-19 vaccine, known as the most innovative application in the world, started last week. In addition, the tests are carried out on 330 volunteers in three groups.

The effectiveness of the virus-like particle (VLP) based domestic Covid-19 vaccine, which started phase-2 studies last week, is being tested in three groups against mutant viruses. The first group is tested against the Wuhan type, the second group against the British type, and the third group against the Wuhan and British type. Ankara Oncology Training and Research Hospital Chief Physician and Head of Phase 1 Clinical Research Center Prof. Dr. Fevzi Altuntas said, “Our plan is to finish phase-2 in July. If everything goes well, we will be ready for phase-3 at the end of August or the beginning of September. “

The VLP vaccine, which was developed by Prof. Dr. Mayda Gursel and Prof. Dr. Ihsan Gursel and continues to work under the roof of TUBITAK COVID-19 Turkey Platform at Ankara Oncology Hospital, has started to be administered to volunteers within the scope of phase-2.

Ankara Oncology Training and Research Hospital Chief Physician and Phase 1 Clinical Research Center Manager Prof. Dr. Fevzi Altuntas, who informed the AA reporter about the ongoing phase-2 studies and the effectiveness of the vaccine against mutant viruses, said that the VLP vaccine is innovative and different from other VLP vaccines in the world.

Altuntas stated that in the VLP vaccine, a similar virus is made with recombinant technology and the non-infectious form is applied to the human, and that it is made suitable for triggering immunity and that the vaccine can be designed against every variant in two weeks.

“OUR PLAN IS TO FINISH IT DURING JULY”

Explaining that the efficacy of the vaccine against variants was tested in three groups in the Phase-2 phase, Altuntas said, “The Phase-2 phase will be carried out with the participation of 330 volunteers. These will be in three groups. The first group will be made with the Wuhan type, the second group with the British type, and the third with the Wuhan and British type. Our plan is to finish it in July. If everything goes well, we will be ready for phase 3 at the end of August and the beginning of September.”

Altuntas stated that the effect of the vaccine against the “delta” variant is theoretically possible, but there is no study on this, and that such a study can be done in the future as the data comes.

“COME, VOLUNTEER FOR OUR VLP VACCINE”

Prof. Dr. Altuntas invited everyone who does not have any health problems, has not had Covid-19 before or has not had any vaccination, and does not have a chronic disease, to volunteer for the local and national VLP vaccine, and said:

“As our President said, if we produce our own vaccine, we will make it available to all humanity. We academics also believe in this philosophy and we want to fulfill it. Therefore, come, volunteer for our VLP vaccine, let’s be useful to all humanity. You can apply for this at ‘www.onkoloji.gov.tr’. When you fill out the application form, we will get back to you as soon as possible.”

VACCINE’S PHASE-1 DATA WILL BE SHARED WITH THE INTERNATIONAL SCIENCE WORLD

Reminding that the efficacy of the vaccine was tested in 36+2 volunteers in the phase-1 study and that no safety problems were encountered either in the examination or in the laboratory, Altuntas said:

“Our domestic vaccine has completed the phase-1 phase and is safe, but of course its follow-up continues. We saw very few side effects such as a slight rash in the clinic, one of which is our Minister, we did not encounter any other side effects. We are currently testing the activity in phase-2, and we will test its effectiveness in phase-3. In addition, we are trying to write down the laboratory and clinical data of the phase-1 phase of our vaccine. I think we’ll have it uploaded this week or next. It will be published in an internationally respected, indexed journal.”

Source: Sabah / Translated by Irem Yildiz

Leave a Reply

Your email address will not be published.

Back to top button